$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

$gthp Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000147793222008459 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$3.000K	$19.00K
YoY Change	-100.0%	-84.21%	-75.32%
Cost Of Revenue	$79.00K	$0.00	$42.00K
YoY Change	315.79%	-100.0%	250.0%
Gross Profit	-$79.00K	$3.000K	-$23.00K
YoY Change	-292.68%	-113.04%	-135.38%
Gross Profit Margin		100.0%	-121.05%
Selling, General & Admin	$830.0K	$1.219M	$448.0K
YoY Change	80.83%	172.1%	153.11%
% of Gross Profit		40633.33%
Research & Development	$39.00K	$8.000K	$16.00K
YoY Change	129.41%	-50.0%	-60.98%
% of Gross Profit		266.67%
Depreciation & Amortization	$3.000K	$1.000K	$1.000K
YoY Change		0.0%
% of Gross Profit		33.33%
Operating Expenses	$869.0K	$1.227M	$464.0K
YoY Change	82.56%	164.44%	112.84%
Operating Profit	-$948.0K	-$1.224M	-$487.0K
YoY Change	117.93%	151.33%	218.3%
Interest Expense	-$56.00K	$155.0K	$594.0K
YoY Change	-45.1%	-73.91%	87.38%
% of Operating Profit
Other Income/Expense, Net	$11.00K	$122.0K	$555.0K
YoY Change	-88.17%	-78.02%	-67.88%
Pretax Income	-$1.807M	-$1.102M	$68.00K
YoY Change	306.98%	-1720.59%	-95.68%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$1.857M	$1.102M	$68.00K
YoY Change	318.24%	1520.59%	-95.68%
Net Earnings / Revenue		36733.33%	357.89%
Basic Earnings Per Share		-$0.03	$0.00
Diluted Earnings Per Share	-$0.04	-$0.03	$0.00
COMMON SHARES
Basic Shares Outstanding	48.58M shares	36.66M shares	13.42M shares
Diluted Shares Outstanding		34.83M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.313M	$2.697M	$541.0K
YoY Change	259.72%	398.52%	-6.88%
Cash & Equivalents	$2.313M	$2.697M	$541.0K
Short-Term Investments
Other Short-Term Assets	$137.0K	$169.0K	$173.0K
YoY Change	-63.66%	-2.31%	-71.31%
Inventory	$548.0K	$596.0K	$590.0K
Prepaid Expenses
Receivables	$6.000K	$29.00K	$24.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.004M	$3.491M	$1.328M
YoY Change	83.51%	162.88%	7.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$42.00K	$42.00K	$11.00K
YoY Change	200.0%	281.82%	-82.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$17.00K	$17.00K	$17.00K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$362.0K	$380.0K	$416.0K
YoY Change	-10.17%	-8.65%	570.97%
TOTAL ASSETS
Total Short-Term Assets	$3.004M	$3.491M	$1.328M
Total Long-Term Assets	$362.0K	$380.0K	$416.0K
Total Assets	$3.366M	$3.871M	$1.744M
YoY Change	65.0%	121.96%	34.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.186M	$2.217M	$2.220M
YoY Change	-7.45%	-0.14%	-18.53%
Accrued Expenses	$1.247M	$1.050M	$32.95K
YoY Change	-29.47%	3087.13%	-98.89%
Deferred Revenue
YoY Change
Short-Term Debt	$288.0K	$686.0K	$861.0K
YoY Change	-65.05%	-20.33%	66.86%
Long-Term Debt Due	$17.00K	$32.00K	$18.00K
YoY Change	-80.68%	77.78%	-99.13%
Total Short-Term Liabilities	$4.869M	$5.146M	$5.076M
YoY Change	-14.49%	1.38%	-38.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.373M
YoY Change	-100.0%	-100.0%	8.62%
Other Long-Term Liabilities	$251.0K	$267.0K	$373.0K
YoY Change	-29.69%	-28.42%	-93.28%
Total Long-Term Liabilities	$1.380M	$1.376M	$1.746M
YoY Change	-22.95%	-21.19%	-74.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.869M	$5.146M	$5.076M
Total Long-Term Liabilities	$1.380M	$1.376M	$1.746M
Total Liabilities	$6.249M	$6.522M	$6.822M
YoY Change	-16.51%	-4.4%	-54.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$147.4M	-$145.5M	-$141.9M
YoY Change	3.49%	2.55%
Common Stock	$3.437M	$3.432M	$3.403M
YoY Change	1.0%	0.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$132.0K	$132.0K	$132.0K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	-$2.883M	-$2.651M	-$5.078M
YoY Change
Total Liabilities & Shareholders Equity	$3.366M	$3.871M	$1.744M
YoY Change	65.0%	121.96%	34.15%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$1.857M	$1.102M	$68.00K
YoY Change	318.24%	1520.59%	-95.68%
Depreciation, Depletion And Amortization	$3.000K	$1.000K	$1.000K
YoY Change		0.0%
Cash From Operating Activities	-$338.0K	-$612.0K	-$739.0K
YoY Change	-312.58%	-17.19%	21.95%
INVESTING ACTIVITIES
Capital Expenditures	$3.000K	$3.000K	-$5.000K
YoY Change	-175.0%	-160.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$3.000K	$3.000K	-$5.000K
YoY Change	-25.0%	-160.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-42.00K	2.860M	363.0K
YoY Change	-20.75%	687.88%	-14.39%
NET CHANGE
Cash From Operating Activities	-338.0K	-612.0K	-739.0K
Cash From Investing Activities	-3.000K	3.000K	-5.000K
Cash From Financing Activities	-42.00K	2.860M	363.0K
Net Change In Cash	-383.0K	2.251M	-381.0K
YoY Change	-475.49%	-690.81%	109.34%
FREE CASH FLOW
Cash From Operating Activities	-$338.0K	-$612.0K	-$739.0K
Capital Expenditures	$3.000K	$3.000K	-$5.000K
Free Cash Flow	-$341.0K	-$615.0K	-$734.0K
YoY Change	-309.2%	-16.21%	21.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	29000	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	46000	usd
CY2022Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	785000	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	497000	usd
CY2022Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	usd
CY2022Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	161000	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	579000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	736000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5146000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5694000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	267000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	325000	usd
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	32000	usd
CY2022Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1017000	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	820000	usd
CY2022Q3	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	92000	usd
CY2021Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	592000	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1376000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1791000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	6522000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	7485000	usd
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	41000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	129000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0000924515
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	785000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13673000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27583000	shares
	gthp	Series F Preferred Offering Amount SeriesFPreferredOfferingAmount	1195000	usd
	gthp	Issuance Of Common Stock To Finders IssuanceOfCommonStockToFinders	54000	usd
	gthp	Issuanceofwarrantstoconsultantsamount Issuanceofwarrantstoconsultantsamount	1093000	usd
	gthp	Warrantsissued Warrantsissued	304000	usd
	gthp	Conversionsofwarrantsfromliabilitytoequity Conversionsofwarrantsfromliabilitytoequity	1755000	usd
	gthp	Stockbasedcompensation Stockbasedcompensation	178000	usd
	gthp	Accruedpreferreddividends Accruedpreferreddividends	-296000	usd
	us-gaap	Profit Loss ProfitLoss	-1626000	usd
CY2021Q3	gthp	Issuance Of Common Stock For Series E Preferred Dividends IssuanceOfCommonStockForSeriesEPreferredDividends	118000	usd
CY2021Q3	gthp	Issuance Of Common Stock For Series D Preferred Dividends Amount IssuanceOfCommonStockForSeriesDPreferredDividendsAmount	11000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1796000	usd
	gthp	Issuance Of Common Stock For Payment Of Interest IssuanceOfCommonStockForPaymentOfInterest	150000	usd
CY2021Q4	gthp	Common Stock Shares Authorized Shares CommonStockSharesAuthorizedShares	500000000	shares
CY2022Q3	gthp	Common Stocks Shares Issued CommonStocksSharesIssued	27583473	shares
CY2022Q3	gthp	Common Stocks Shares Outstanding CommonStocksSharesOutstanding	27583473	shares
CY2022Q3	gthp	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Ending Balance SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceEndingBalance	0.49
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.47
	gthp	Options Granted Expiration Term OptionsGrantedExpirationTerm	P10Y
	gthp	Options Granted Exercisable Term OptionsGrantedExercisableTerm	P4Y
CY2021Q4	gthp	Financing Agreement Amount FinancingAgreementAmount	1000000	usd
	gthp	Price Of Share PriceOfShare	1000.00	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Entity File Number EntityFileNumber	0-22179
	dei	Entity Registrant Name EntityRegistrantName	GUIDED THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	58-2029543
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5835 Peachtree Corners East
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite B
	dei	Entity Address City Or Town EntityAddressCityOrTown	Norcross
	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30092
	dei	City Area Code CityAreaCode	770
	dei	Local Phone Number LocalPhoneNumber	242-8723
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48578721	shares
CY2022Q3	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	48000	usd
CY2021Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	126000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	usd
CY2022Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	19000	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	22000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-89000	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	270000	usd
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27583000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13673000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3403000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	126800000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	132000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-142387000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2651000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5445000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2040000	usd
CY2022Q3	us-gaap	Revenues Revenues	3000	usd
CY2021Q3	us-gaap	Revenues Revenues	19000	usd
	us-gaap	Revenues Revenues	13000	usd
	us-gaap	Revenues Revenues	21000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	42000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	42000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	3000	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	-23000	usd
	us-gaap	Gross Profit GrossProfit	11000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	107000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1167000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	407000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2229000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	1227000	usd
	us-gaap	Operating Expenses OperatingExpenses	1906000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-487000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2385000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1927000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	155000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	594000	usd
	us-gaap	Interest Expense InterestExpense	512000	usd
	us-gaap	Interest Expense InterestExpense	1050000	usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	5000	usd
CY2021Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1000	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	13000	usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	763000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	345000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	578000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1796000	usd
CY2022Q3	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	10000	usd
CY2022Q3	gthp	Issuanceofcommonstockforpaymentof Series Epreferreddividendsamount IssuanceofcommonstockforpaymentofSeriesEpreferreddividendsamount	67000	usd
CY2022Q3	gthp	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	0	usd
CY2021Q3	gthp	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	0	usd
	gthp	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	0	usd
	gthp	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	448000	usd
CY2022Q3	us-gaap	Other Income OtherIncome	2000	usd
CY2021Q3	us-gaap	Other Income OtherIncome	387000	usd
	us-gaap	Other Income OtherIncome	5000	usd
	us-gaap	Other Income OtherIncome	414000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	122000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	555000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-149000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	301000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1102000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	68000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2534000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1626000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1102000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	68000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2534000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1626000	usd
CY2022Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	48000	usd
CY2021Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	119000	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	581000	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	296000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1054000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-51000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3115000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1922000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2022Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	34829000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	13417000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	27335000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	13291000	shares
CY2022Q3	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	34829000	shares
CY2021Q3	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	13417000	shares
	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	27335000	shares
	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	13291000	shares
CY2022Q3	gthp	Issuances Of Common Stock To Investors Amount IssuancesOfCommonStockToInvestorsAmount	1396000	usd
CY2022Q3	gthp	Issuance Of Common Stock For Payment Of Interest Amount IssuanceOfCommonStockForPaymentOfInterestAmount	70000	usd
CY2022Q3	gthp	Conversion Of Series F2 Preferred Stock To Common Stock Amount ConversionOfSeriesF2PreferredStockToCommonStockAmount	0	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	44000	usd
CY2022Q3	gthp	Issuances Of Warrants To Consultants IssuancesOfWarrantsToConsultants	786000	usd
CY2022Q3	gthp	Accrued Preferred Dividends AccruedPreferredDividends	48000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-1102000	usd
	gthp	Series F2 Preferred Offering Shares SeriesF2PreferredOfferingShares	404000	usd
	gthp	Conversion Of Debt And Expenses For Series F2 Preferred Stock Shares ConversionOfDebtAndExpensesForSeriesF2PreferredStockShares	2559000	usd
	gthp	Issuance Of Common Stock For Series D Preferred Dividends Amount IssuanceOfCommonStockForSeriesDPreferredDividendsAmount	39000	usd
	us-gaap	Profit Loss ProfitLoss	-2534000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2651000	usd
	gthp	Conversion Of Series E Preferred Stock To Common Stock Amount ConversionOfSeriesEPreferredStockToCommonStockAmount	0	usd
	gthp	Conversion Of Series F Preferred Stock To Common Stock Amount ConversionOfSeriesFPreferredStockToCommonStockAmount	0	usd
	gthp	Conversion Of Series F2 Preferred Stock To Common Stock Amount ConversionOfSeriesF2PreferredStockToCommonStockAmount	0	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-7992000	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	56000	usd
CY2021Q3	gthp	Accrued Preferred Dividends AccruedPreferredDividends	-119000	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	68000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-7746000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-10855000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2651000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-5445000	usd
	gthp	Common Stock Warrants Exercised Amount CommonStockWarrantsExercisedAmount	846000	usd
	gthp	Issuances Of Common Stock To Investors Amount IssuancesOfCommonStockToInvestorsAmount	1396000	usd
	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	39000	usd
	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividends	102000	usd
	gthp	Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount	107000	usd
	gthp	Issuance Of Common Stock For Payment Of Interest Amount IssuanceOfCommonStockForPaymentOfInterestAmount	150000	usd
	gthp	Issuance Of Common Stock For Series F And Series F2 One Time15 Dividends Amount IssuanceOfCommonStockForSeriesFAndSeriesF2OneTime15DividendsAmount	400000	usd
	gthp	Conversion Of Series D Preferred Stock To Common Stock Amount ConversionOfSeriesDPreferredStockToCommonStockAmount	1000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	132000	usd
	gthp	Accrued Preferred Dividends AccruedPreferredDividends	-581000	usd
	gthp	Issuance Of Common Stock For Series E Preferred Dividends Amount IssuanceOfCommonStockForSeriesEPreferredDividendsAmount	118000	usd
	gthp	Series G Redemptionamount SeriesGRedemptionamount	178000	usd
	gthp	Series G Preferred Offering Amount SeriesGPreferredOfferingAmount	-1626000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2534000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1626000	usd
	us-gaap	Depreciation Depreciation	1000	usd
	us-gaap	Depreciation Depreciation	1000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	111000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	250000	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	37000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	132000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	178000	usd
	gthp	Increase Decrease In Fair Value Of Warrants IncreaseDecreaseInFairValueOfWarrants	0	usd
	gthp	Increase Decrease In Fair Value Of Warrants IncreaseDecreaseInFairValueOfWarrants	-448000	usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0	usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	84000	usd
	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-13000	usd
	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	89000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	50000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	66000	usd
	gthp	Expense For Warrants Issued To Consultants ExpenseForWarrantsIssuedToConsultants	865000	usd
	gthp	Expense For Warrants Issued To Consultants ExpenseForWarrantsIssuedToConsultants	585000	usd
	gthp	Gain From Extinguishment Of Debt GainFromExtinguishmentOfDebt	-345000	usd
	gthp	Gain From Extinguishment Of Debt GainFromExtinguishmentOfDebt	-578000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	156000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	109000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-25000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	332000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-88000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-17000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-435000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-51000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-41000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	172000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	237000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1140000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1751000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	495000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	gthp	Proceeds From Debt Financing ProceedsFromDebtFinancing	0	usd
	gthp	Proceeds From Debt Financing ProceedsFromDebtFinancing	1248000	usd
	gthp	Payments Made On Notes Payable PaymentsMadeOnNotesPayable	-465000	usd
	gthp	Payments Made On Notes Payable PaymentsMadeOnNotesPayable	-1415000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	86000	usd
	gthp	Note Payable Default Penalty NotePayableDefaultPenalty	0	usd
	gthp	Note Payable Default Penalty NotePayableDefaultPenalty	398000	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	1396000	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	usd
	gthp	Proceeds From Issuances Of Warrants Net Of Costs ProceedsFromIssuancesOfWarrantsNetOfCosts	1796000	usd
	gthp	Proceeds From Issuances Of Warrants Net Of Costs ProceedsFromIssuancesOfWarrantsNetOfCosts	0	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1436000	usd
	gthp	Proceeds From Series F2 Offering Net Of Costs ProceedsFromSeriesF2OfferingNetOfCosts	0	usd
	gthp	Proceeds From Series F2 Offering Net Of Costs ProceedsFromSeriesF2OfferingNetOfCosts	539000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	125000	usd
	gthp	Redemption Of Series G Preferred Stock RedemptionOfSeriesGPreferredStock	0	usd
	gthp	Redemption Of Series G Preferred Stock RedemptionOfSeriesGPreferredStock	-125000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3222000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2120000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2054000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	359000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	643000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	182000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2697000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	541000	usd
	us-gaap	Interest Paid InterestPaid	89000	usd
	us-gaap	Interest Paid InterestPaid	552000	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	581000	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	296000	usd
	gthp	Settlement Of Interest Through Common Stock Issuance SettlementOfInterestThroughCommonStockIssuance	151000	usd
	gthp	Settlement Of Interest Through Common Stock Issuance SettlementOfInterestThroughCommonStockIssuance	0	usd
	gthp	Debt From Related Parties Exchanged For Preferred Series F2 Shares DebtFromRelatedPartiesExchangedForPreferredSeriesF2Shares	0	usd
	gthp	Debt From Related Parties Exchanged For Preferred Series F2 Shares DebtFromRelatedPartiesExchangedForPreferredSeriesF2Shares	323000	usd
	gthp	Issuance Of Series F2 Preferred Stock IssuanceOfSeriesF2PreferredStock	0	usd
	gthp	Issuance Of Series F2 Preferred Stock IssuanceOfSeriesF2PreferredStock	2236000	usd
	gthp	Issuance Of Warrants To Finders In Connection With Series F And Series F2 Preferred Stock IssuanceOfWarrantsToFindersInConnectionWithSeriesFAndSeriesF2PreferredStock	0	usd
	gthp	Issuance Of Warrants To Finders In Connection With Series F And Series F2 Preferred Stock IssuanceOfWarrantsToFindersInConnectionWithSeriesFAndSeriesF2PreferredStock	377000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	722000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	157000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	62000	usd
	gthp	Non Cash Warrants Exchanged For Fixed Price Warrants NonCashWarrantsExchangedForFixedPriceWarrants	0	usd
	gthp	Non Cash Warrants Exchanged For Fixed Price Warrants NonCashWarrantsExchangedForFixedPriceWarrants	1755000	usd
	gthp	Warrants Issued With Debt WarrantsIssuedWithDebt	0	usd
	gthp	Warrants Issued With Debt WarrantsIssuedWithDebt	304000	usd
	gthp	Conversion Of Series D Preferred Shares Into Common Stock ConversionOfSeriesDPreferredSharesIntoCommonStock	118000	usd
	gthp	Conversion Of Series D Preferred Shares Into Common Stock ConversionOfSeriesDPreferredSharesIntoCommonStock	0	usd
	gthp	Conversion Of Series E Preferred Shares Into Common Stock ConversionOfSeriesEPreferredSharesIntoCommonStock	800000	usd
	gthp	Conversion Of Series E Preferred Shares Into Common Stock ConversionOfSeriesEPreferredSharesIntoCommonStock	0	usd
	gthp	Conversion Of Series F Preferred Shares Into Common Stock ConversionOfSeriesFPreferredSharesIntoCommonStock	296000	usd
	gthp	Conversion Of Series F Preferred Shares Into Common Stock ConversionOfSeriesFPreferredSharesIntoCommonStock	0	usd
	gthp	Conversion Of Series F2 Preferred Shares Into Common Stock ConversionOfSeriesF2PreferredSharesIntoCommonStock	2473000	usd
	gthp	Conversion Of Series F2 Preferred Shares Into Common Stock ConversionOfSeriesF2PreferredSharesIntoCommonStock	0	usd
	gthp	Directors And Officers Insurance Obtained With Financing DirectorsAndOfficersInsuranceObtainedWithFinancing	124000	usd
	gthp	Directors And Officers Insurance Obtained With Financing DirectorsAndOfficersInsuranceObtainedWithFinancing	0	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>1. </strong><strong>ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the continued commercialization of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2021, the Board simultaneously approved a 1-for-20 reverse stock split of our common stock and decreased the total number of authorized common shares to 500,000,000. On November 18, 2021, the Company submitted an Issuer Company Related Action Notification regarding the reverse stock split to the Financial Industry Regulatory Authority (“FINRA”). On July 25, 2022, the Company filed a Certificate of Correction with the Secretary of State of Delaware to render null and void <em>ab initio</em> the Reverse Split Amendment and as a result, the Reverse Split was deemed null and void. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Basis of Presentation </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934. The December 31, 2021 balances reported herein are derived from the audited consolidated financial statements for the year ended December 31, 2021. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company as of September 30, 2022 and December 31, 2021, and the consolidated results of operations and cash flows for the three and nine-month periods ended September 30, 2022 and 2021 have been included. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of September 30, 2022, it had an accumulated deficit of approximately $145.5 million. To date, the Company has engaged primarily in research and development efforts and the early stages of marketing its products. The Company may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. The Company’s products may not ever gain market acceptance and the Company may not ever generate significant revenues or achieve profitability. The development and commercialization of the Company’s products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue for the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals, build its marketing, sales, manufacturing and finance capabilities, and conduct further research and development.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is not organized by multiple operating segments for the purpose of making operating decisions or assessing performance. Accordingly, the Company operates in one reportable operating segment. The Company’s principal decision makers are the Chief Executive Officer and its Chief Financial Officer. Management believes that its business operates as one reportable segment because: a) the Company measures profit and loss as a whole; b) the principal decision makers do not review information based on any operating segment; c) the Company does not maintain discrete financial information on any specific segment; d) the Company has not chosen to organize its business around different products and services, and e) the Company has not chosen to organize its business around geographic areas.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Going Concern</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At September 30, 2022, the Company had a negative working capital of approximately $1.8 million, accumulated deficit of $145.5 million and incurred a net loss including preferred dividends of $3.1 million for the nine months then ended. Stockholders’ deficit totaled approximately $2.7 million at September 30, 2022, primarily due to recurring net losses from operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine-month period ended September 30, 2022, the Company raised $3.2 million from the sale of common stock and warrants (net of expenses), and $495 thousand of proceeds from warrant exercises. The Company will need to continue to raise capital in order to provide funding for its operations and FDA approval process. If sufficient capital cannot be raised, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company had warrants exercisable for approximately 40.1 million shares of its common stock outstanding at September 30, 2022, with exercise prices ranging between $0.15 and $0.80 per share. Exercises of in-the-money warrants would generate a total of approximately $8.6 million in cash, assuming full exercise, although the Company cannot be assured that holders will exercise any warrants. Management may obtain additional funds through the public or private sale of debt or equity, and grants, if available.</p>
CY2021Q4	gthp	Decrease In Authorized Common Share DecreaseInAuthorizedCommonShare	500000000	shares
CY2022Q3	gthp	Working Capital WorkingCapital	1800000	usd
CY2022Q3	gthp	Accumulated Deficit AccumulatedDeficit	145500000	shares
	gthp	Net Loss Including Preferred Dividend NetLossIncludingPreferredDividend	3100000	usd
CY2022Q3	gthp	Stockholder Equity StockholderEquity	2700000	usd
	gthp	Proceeds From Sale Of Common Stock ProceedsFromSaleOfCommonStock	3200000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	495000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of embedded conversion options and freestanding warrants.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.</p>
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14000	usd
CY2022Q3	gthp	Accrued Stock Subscription Payable AccruedStockSubscriptionPayable	0	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1274000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1255000	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	70000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	69000	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	37000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	32000	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	785000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	785000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	596000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	571000	usd
CY2021Q4	gthp	Accrued Stock Subscription Payable AccruedStockSubscriptionPayable	351000	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	182000	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	261000	usd
CY2022Q3	gthp	Subtotal Subtotal	1791000	usd
CY2021Q4	gthp	Subtotal Subtotal	1761000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1749000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1747000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	126000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	98000	usd
CY2022Q3	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	488000	usd
CY2021Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	621000	usd
CY2022Q3	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	42000	usd
CY2021Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	39000	usd
CY2022Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent	190000	usd
CY2021Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	349000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	22000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	49000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1050000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1768000	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	509101	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	337315	usd
CY2022Q3	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	298884	usd
	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	344584	usd
	gthp	Decrease Net Income Loss DecreaseNetIncomeLoss	344584	usd
CY2022Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	77634	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	48172	usd
CY2022Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	29462	usd
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	171153	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	125584	usd
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	45569	usd
CY2022Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	61600000	usd
	us-gaap	Premiums Percentage Assumed To Net PremiumsPercentageAssumedToNet	0.50	pure
	gthp	Warrants Warrants	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model.</p>
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	-19000	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	-32000	usd
	gthp	Summary Of Changes To Level3 Instruments SummaryOfChangesToLevel3Instruments	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>(in thousands)</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Senior Secured </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Derivative</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Balance, December 31, 2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in fair value during the period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Balance, September 30, 2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(19</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(19</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr></tbody></table>
CY2022Q3	gthp	Common Stock Shares Issued1 CommonStockSharesIssued1	6636540	shares
CY2022Q3	gthp	Aggregate Shares Of Common Stock AggregateSharesOfCommonStock	6636540	usd
CY2022Q3	us-gaap	Preferred Stock Dividends Shares PreferredStockDividendsShares	65000	shares
CY2022Q3	gthp	Aggregate Purchase Price AggregatePurchasePrice	3318270	usd
CY2022Q3	gthp	Common Stock Shares Authorized Shares CommonStockSharesAuthorizedShares	500000000	shares
CY2021Q4	gthp	Common Stocks Shares Issued CommonStocksSharesIssued	43418443	shares
CY2021Q4	gthp	Common Stocks Shares Outstanding CommonStocksSharesOutstanding	13673583	shares
	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	29744860	shares
	gthp	Schedule Common Stock Issued Table Textblock ScheduleCommonStockIssuedTableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number of Shares </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuances of common stock to investors</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,636,540</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuances of common stock for warrants exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,127,923</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuances of common stock for payment of Series D Preferred dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,979</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuances of common stock for payment of Series E Preferred dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">179,858</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuances of common stock for payment of Series F Preferred dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">162,436</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuances of common stock for payment of Series F-2 Preferred dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">114,304</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuances of common stock for payment of interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">241,914</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuances of common stock for Series F one-time 15% dividend</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">255,401</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuances of common stock for Series F-2 one-time 15% dividend</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">368,505</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Conversion of Series D Preferred stock to common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">975,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Conversion of Series E Preferred stock to common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,390,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Conversion of Series F Preferred stock to common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,420,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Conversion of Series F-2 Preferred stock to common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,808,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issued during the nine months ended September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">29,744,860</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Summary table of common stock share transactions:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,673,583</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issued in 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">29,744,860</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares outstanding at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">43,418,443</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
	gthp	Issuance Of Common Stock To Investors IssuanceOfCommonStockToInvestors	6636540	shares
	gthp	I Ssuanceofcommonstockforwarrantsexercised ISsuanceofcommonstockforwarrantsexercised	5127923	shares
	gthp	Stock Issued During Period Shares Issued For Series D Dividends StockIssuedDuringPeriodSharesIssuedForSeriesDDividends	64979	shares
	gthp	Stock Issued During Period Shares Issued For Series F Dividends StockIssuedDuringPeriodSharesIssuedForSeriesFDividends	179858	shares
	gthp	Issuance Of Common Stock For Payment Of Series F Preferred Dividends IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividends	162436	shares
	gthp	Stock Issued During Period Shares Issued For Series F2 Dividends StockIssuedDuringPeriodSharesIssuedForSeriesF2Dividends	114304	shares
	gthp	Stock Issued During Period Shares Issued For Payment Of Interest StockIssuedDuringPeriodSharesIssuedForPaymentOfInterest	241914	shares
	gthp	Stock Issued During Period Shares Issued For Series F One Time Dividend StockIssuedDuringPeriodSharesIssuedForSeriesFOneTimeDividend	255401	shares
	gthp	Stock Issued During Period Shares Issued For Series F2 One Time Dividend StockIssuedDuringPeriodSharesIssuedForSeriesF2OneTimeDividend	368505	shares
	gthp	Conversion Of Stock D Shares Issued1 ConversionOfStockDSharesIssued1	975000	shares
	gthp	Conversion Of Stock E Shares Issued1 ConversionOfStockESharesIssued1	3390000	shares
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	1420000	shares
	gthp	Conversion Of Stock Shares F2 Issued1 ConversionOfStockSharesF2Issued1	10808000	shares
	gthp	Stock Issued During Period StockIssuedDuringPeriod	29744860	shares
CY2020	gthp	Shares Outstanding One SharesOutstandingOne	13673583	shares
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	29744860	shares
	gthp	Shares Outstanding One SharesOutstandingOne	43418443	shares
CY2022Q3	gthp	Convertible Notes Payable Short Term ConvertibleNotesPayableShortTerm	679000	usd
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	1420000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	27669634	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.29
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	15323080	shares
	gthp	Weighted Average Exercise Price Per Share Issued WeightedAverageExercisePricePerShareIssued	0.54
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1000	shares
	gthp	Weighted Average Exercise Price Per Share Expired WeightedAverageExercisePricePerShareExpired	0.50
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	2934324	shares
	gthp	Share Based Compensation Arrangements By Share Based Payment Award Options Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice	0.17
	gthp	Warrants Outstanding WarrantsOutstanding	40057390	shares
	gthp	Weighted Average Exercise Price Per Share Outstanding WeightedAverageExercisePricePerShareOutstanding	0.40
CY2022Q3	gthp	Warrants Issued To Investors WarrantsIssuedToInvestors	13273080	shares
CY2022Q3	gthp	Issuanceof Shares Warrnts IssuanceofSharesWarrnts	2050000	shares
	gthp	Fair Value Of The Warrants Issuedtabletextblock FairValueOfTheWarrantsIssuedtabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected term (years)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3.8 Years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">151.19</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.30</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>
	us-gaap	Debt Instrument Term DebtInstrumentTerm	P3Y9M18D
	gthp	Volatility Volatility	1.5119	pure
	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.0330	pure
	gthp	Dividend Yield DividendYield	0.0000	pure
CY2022Q3	gthp	Common Shares For Warrants Exercised CommonSharesForWarrantsExercised	5127923	shares
CY2021Q4	gthp	Common Shares For Warrants Exercised CommonSharesForWarrantsExercised	2193599	shares
	gthp	Received From The Stock Holders ReceivedFromTheStockHolders	351000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.10	pure
	gthp	Outstanding End OutstandingEnd	1500000	shares
	gthp	Weighted Average Remaining Contractual Life Outstanding1 WeightedAverageRemainingContractualLifeOutstanding1	P7Y9M18D
	gthp	Agrregate Intrensic Value Outstanding AgrregateIntrensicValueOutstanding	0	usd
	gthp	Number Of Shares Exercisable NumberOfSharesExercisable	1227136	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.49
	gthp	Weighted Average Remaining Contractual Life Exercisable1 WeightedAverageRemainingContractualLifeExercisable1	P7Y9M18D
	gthp	Agrregate Intrensic Value Exercisable AgrregateIntrensicValueExercisable	0	usd
CY2022Q3	gthp	Unrecognized Stock Based Compensation Expense UnrecognizedStockBasedCompensationExpense	131735	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.47
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	321000	usd
CY2022Q3	gthp	Operating Lease Liability One OperatingLeaseLiabilityOne	343000	usd
CY2021Q4	gthp	Convertible Notes Payable Short Term ConvertibleNotesPayableShortTerm	897000	usd
	gthp	Maturities Of Operating Lease Liabilities Tabletextblock MaturitiesOfOperatingLeaseLiabilitiesTabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>(in thousands)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Operating</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td/><td/><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Lease Payments</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2022 (remaining)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">112</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">115</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">118</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">50</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total future lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">422</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less: discount</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(79</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">343</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	27000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	112000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	115000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	118000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	50000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	422000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	79000	usd
CY2022Q3	gthp	Operating Lease Liabilities OperatingLeaseLiabilities	-343000	usd
	us-gaap	Finite Lived Intangible Asset Weighted Average Period Before Next Renewal Or Extension FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension	P3Y8M12D
	gthp	Weighted Average Discount Rateoperating Lease WeightedAverageDiscountRateoperatingLease	0.114	pure
CY2016Q2	gthp	Royalty Percent RoyaltyPercent	0.20	pure
CY2020Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5000000	shares
CY2020Q1	gthp	Warrants Broken Into Four Tranches WarrantsBrokenIntoFourTranches	1250000	shares
CY2020Q1	us-gaap	Share Price SharePrice	0.25
CY2019Q3	gthp	Consideration Received ConsiderationReceived	885144	usd
CY2019Q3	gthp	Escrow Agent Rate Per Share EscrowAgentRatePerShare	1.90
CY2022Q3	us-gaap	Line Of Credit Facility Average Outstanding Amount LineOfCreditFacilityAverageOutstandingAmount	123889	usd
CY2022Q3	us-gaap	Notes Payable NotesPayable	89947	usd
CY2022Q3	gthp	Short Term Notes Payable Due To Related Parties ShortTermNotesPayableDueToRelatedParties	17154	usd
	gthp	Decrease Net Income Loss DecreaseNetIncomeLoss	85000	usd
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.14
CY2022Q3	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	107000	usd
CY2021Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	88000	usd
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	39900	usd
CY2021Q4	gthp	Short Term Notes Payable Due To Related Parties ShortTermNotesPayableDueToRelatedParties	87514	usd
	gthp	Auctus Convertible Debt Disclosuretextblock AuctusConvertibleDebtDisclosuretextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>9. AUCTUS CONVERTIBLE DEBT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 17, 2019, the Company entered into a securities purchase agreement and convertible note with Auctus. The convertible note issued to Auctus was for a total of $2.4 million. The note may not have been prepaid in whole or in part except as otherwise explicitly allowed. Any amount of principal or interest on the note which was not paid when due shall bore interest at the rate of the lessor of 24% or the maximum permitted by law (the “default interest”). The variable conversion prices equaled the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event could the variable conversion price be less than $0.15. If an event of default under this note occurred and/or the note was not extinguished in its entirety prior to December 17, 2020, the $0.15 price floor no longer applied.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 1, 2022, the Company has agreed to exchange certain debt and equity owned by Auctus pursuant to an Exchange Agreement between the Company and Auctus (the “Exchange Agreement”). Immediately prior to the Exchange Agreement, Auctus held $1,228,183 of debt, including early prepayment penalty of $350,000, default premiums of $281,256, and $91,555 in interest payable. Auctus agreed to exchange the above balance for $710,911 in debt owed and to revert the May 27, 2020 note to its original term. Auctus currently holds 8,775,000 warrants that are priced between $0.15 and $0.20, and for the value of $1,950,000, which includes the value of the warrant and $350,000 in early prepayment penalty, agreed to exchange it for 3,900,000 common shares, warrants to purchase 3,900,000 common shares at $0.50 per share and warrants to purchase 3,900,000 common shares at $0.65 per share (the “Exchange”). Auctus agreed the equity instruments will be issued and exchanged in the fourth quarter of 2022 (see Note 12, “Subsequent Events”). As a result of the Exchange Agreement, Auctus forgave a default penalty of $225,444. In addition, the Company made a repayment of $221,467 to Auctus pursuant to the terms of the Exchange Agreement (the “Repayment”), of which $161,184 was applied to principal and penalties and $60,283 was applied to interest payable. Following the Exchange and Repayment, the Company will make payments to Auctus in four installments, over an 18-month period. The first installment of $125,000 was paid on September 8, 2022, of which $101,116 was applied to outstanding principal and $23,884 was applied to interest payable. The transaction was accounted for in accordance with ASC 470-60, Troubled Debt Restructurings (“TDR”) by Debtors. As a result of the Exchange Agreement, the Company recorded a gain on extinguishment of debt of $186,527 during the three months ended September 30, 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table summarizes the Auctus Convertible Notes Payable:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>September 30, 2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Auctus Tranche 2</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">329</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Auctus prepayment penalty</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">350</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">350</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Auctus (March 31, 2020 Note)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">161</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Debt discount and issuance costs to be amortized</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong> Auctus convertible notes payable</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>679</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>897</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2022, $579,000 of the total balance owed to Auctus is included in “Short-term convertible notes payable, including non-convertible penalty” within the unaudited consolidated balance sheet. The remaining balance is included in “Long-term convertible debt” within the unaudited consolidated balance sheet. As of December 31, 2021, the $161,000 Auctus note was included in “Convertible notes payable in default” while the remaining balances were included in “Short-term convertible notes payable, including non-convertible penalty” within the consolidated balance sheet. </p>
CY2019Q4	gthp	Description Of Variable Conversion Prices DescriptionOfVariableConversionPrices	The variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event could the variable conversion price be less than $0.15. If an event of default under this note occurred and/or the note was not extinguished in its entirety prior to December 17, 2020, the $0.15 price floor no longer applied.
	gthp	Description Of Price DescriptionOfPrice	warrants that are priced between $0.15 and $0.20, and for the value of $1,950,000, which includes the value of the warrant and $350,000 in early prepayment penalty, agreed to exchange it for 3,900,000 common shares, warrants to purchase 3,900,000 common shares at $0.50 per share and warrants to purchase 3,900,000 common shares at $0.65 per share (the “Exchange”). Auctus agreed the equity instruments will be issued and exchanged in the fourth quarter of 2022 (see Note 12, “Subsequent Events”). As a result of the Exchange Agreement, Auctus forgave a default penalty of $225,444
CY2022Q3	gthp	Debt Discount And Issuance Costs To Be Amortized DebtDiscountAndIssuanceCostsToBeAmortized	0	usd
CY2021Q4	gthp	Debt Discount And Issuance Costs To Be Amortized DebtDiscountAndIssuanceCostsToBeAmortized	-14000	usd
CY2022Q2	us-gaap	Repurchase Agreements Interest Expense Amount RepurchaseAgreementsInterestExpenseAmount	29776	usd
CY2022Q2	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	31285	usd
CY2022Q2	us-gaap	Accretion Expense AccretionExpense	8939	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	70000	usd
CY2022Q2	us-gaap	Direct Financing Lease Revenue DirectFinancingLeaseRevenue	4000000	usd
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	27335000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	13291000	shares
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.11
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.14
	gthp	Total Dilutive Instruments TotalDilutiveInstruments	23092000	usd
	gthp	Total Dilutive Instruments TotalDilutiveInstruments	37976000	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	590000	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	497170	usd
CY2022Q2	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	92399	usd
	gthp	Bond Payable Discount And Unamortized Debt Issuance Costs BondPayableDiscountAndUnamortizedDebtIssuanceCosts	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Senior Secured Convertible Debenture</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">10% Senior Unsecured Convertible Debentures</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,130</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,130</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Debt Issuance costs to be amortized</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(48</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(69</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Debt Discount</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:right;">(165</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:right;">(241</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Senior Secured Convertible Debenture</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><strong>917</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><strong>820</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr></tbody></table>
CY2022Q3	gthp	Senior Unsecured Convertible Debentures SeniorUnsecuredConvertibleDebentures	1130000	usd
CY2021Q4	gthp	Senior Unsecured Convertible Debentures SeniorUnsecuredConvertibleDebentures	1130000	usd
CY2022Q3	gthp	Debt Issuance Costs Amortized DebtIssuanceCostsAmortized	-48000	usd
CY2021Q4	gthp	Debt Issuance Costs Amortized DebtIssuanceCostsAmortized	-69000	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	165000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	241000	usd
CY2022Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	917000	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	820000	usd
CY2022Q3	gthp	Current Portion Of Long Term Debt CurrentPortionOfLongTermDebt	32052	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3115000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1922000	usd
	us-gaap	Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma	27335000	shares
	us-gaap	Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma	13291000	shares
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.11
	gthp	Price Of Share PriceOfShare	1000.00	shares
CY2022Q3	us-gaap	Price Risk Cash Flow Hedge Liability At Fair Value PriceRiskCashFlowHedgeLiabilityAtFairValue	50000	usd
CY2022Q3	gthp	Share Price Of Common Stock SharePriceOfCommonStock	65000	usd
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	75000	shares
CY2022Q3	gthp	Aggregate Shares Of Common Stock To Purchase Price AggregateSharesOfCommonStockToPurchasePrice	75000	usd

Files In Submission

Name	View Source	Status
0001477932-22-008459-index-headers.html	Edgar Link	pending
0001477932-22-008459-index.html	Edgar Link	pending
0001477932-22-008459.txt	Edgar Link	pending
0001477932-22-008459-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gthp-20220930.xsd	Edgar Link	pending
gthp_10q.htm	Edgar Link	pending
gthp_ex106.htm	Edgar Link	pending
gthp_ex31.htm	Edgar Link	pending
gthp_ex32.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
gthp-20220930_cal.xml	Edgar Link	unprocessable
gthp-20220930_def.xml	Edgar Link	unprocessable
gthp-20220930_pre.xml	Edgar Link	unprocessable
gthp-20220930_lab.xml	Edgar Link	unprocessable
gthp_10q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

2022 Q4 Form 10-Q Financial Statement

#000147793222008459 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP GUIDED THERAPEUTICS INC Stock $gthp

2022 Q4 Form 10-Q Financial Statement

#000147793222008459 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp